Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin and Rifabutin Regimens for MAC Lung Disease
NCT00598897Phase 4Completed
- Sponsor
- The University of Texas Health Science Center at Tyler
- Start
- Aug 1995
- Primary completion
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clarithromycin and rifabutin in Mycobacterium avium complex lung disease, sponsored by The University of Texas Health Science Center at Tyler. Primary endpoint: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures at 6 months. Started Aug 1995; status: completed.
02
Drugs
clarithromycinrifabutin
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT00598897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598897.